Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B

Inclusion Criteria: * Infants are at age of DTP vaccination of the local EPI program (60-120 days old) and free from any obvious health problems * Have a normal gestational age (≥ 37 weeks); birth weight \> 2.5 kg * There is no congenital disease detected through interview and clinical examination * Already had or not yet received Hepatitis B vaccination at birth * Do not have dermatological diseases such as eczema, allergies * Parent or legal guardian voluntarily provides consent for their child for participation in the study by signing the informed consent and agrees to comply with all study procedures Exclusion Criteria: * Already vaccinated with DTP vaccine * Have an acute infection at the time of study vaccination * Contraindications to Quinvaxem * Receiving treatment with systemic corticosteroids * Currently participating in another clinical trial * In receipt of a parenteral immunoglobulin preparation and/or blood/blood products since birth * Parents intend to move to another location during the study (the next 12 months)